Anticipate significant positive stock movement ahead of the ASCO plenary presentation on May 31, 2026, especially if full data confirms survival benefit and safety profile. This could accelerate FDA approval and position daraxonrasib as a new standard of care in a high-mortality indication with limited options.
Price Chart
Executive Summary
Revolution Medicines announced that detailed results from its Phase 3 RASolute 302 trial of daraxonrasib in metastatic pancreatic cancer will be presented at ASCO 2026, following previously reported unprecedented overall survival benefit. The drug met all primary and key secondary endpoints, including statistically significant improvements in progression-free and overall survival versus chemotherapy.
Key Facts
- Daraxonrasib demonstrated statistically significant and clinically meaningful improvement in both PFS and OS vs standard chemotherapy in previously treated metastatic PDAC.
- Results from the Phase 3 RASolute 302 trial will be presented in a Plenary Session at ASCO 2026 — a high-profile venue indicating clinical importance.
- FDA has granted Breakthrough Therapy and Orphan Drug Designations for daraxonrasib; it is also part of the FDA Commissioner’s National Priority Voucher program.
- The trial included patients with various RAS mutations (G12D, G12V, G12R) and RAS wild-type, broadening potential applicability.
- Daraxonrasib is an oral, once-daily RAS(ON) multi-selective inhibitor, offering a convenient alternative to intravenous chemotherapy.
Financial Impact
Potential blockbuster drug with peak sales estimates exceeding $5B annually in metastatic pancreatic cancer alone, based on unmet need and trial results.
Risk Factors
- Regulatory approval is not guaranteed despite Breakthrough designation; FDA may require additional data.
- Safety concerns could emerge in full dataset, limiting commercial potential.
- Competition from other RAS inhibitors in development may affect market share post-approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278211 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 16d ago | 144 | $195.92 $190.74 | ▼ −2.64% | ▼ −5.21% | $206.29 (+5.29%) |
Sep 15, 2026 16d ago | 144 | $195.92 $190.74 | ▼ −2.64% | ▼ −5.21% | $206.29 (+5.29%) |
Sep 15, 2026 17d ago | Insider Cluster | $204.86 $190.95 | ▼ −6.79% | ▼ −7.61% | $206.29 (+0.70%) |
Sep 14, 2026 17d ago | Insider Cluster | $204.86 $192.86 | ▼ −5.86% | ▼ −7.98% | $206.29 (+0.70%) |
Aug 26, 2026 5w ago | 8-K | $215.44 $209.23 | ▼ −2.88% | ▼ −2.76% | $206.29 (−4.25%) |
Aug 26, 2026 5w ago | Press Release | $215.44 $209.23 | ▼ −2.88% | ▼ −2.76% | $206.29 (−4.25%) |
Aug 25, 2026 5w ago | Insider Cluster | $211.38 $209.87 | ▼ −0.71% | ▼ −0.18% | $206.29 (−2.41%) |
Jul 2, 2026 13w ago | Press Release | $189.24 $191.13 | ▲ +1.00% | ▲ +0.07% | $206.29 (+9.01%) |
Jul 1, 2026 13w ago | Insider Cluster | $187.51 $190.46 | ▲ +1.57% | ▲ +1.31% | $206.29 (+10.02%) |
Jun 22, 2026 14w ago | 8-K | $165.81 $192.62 | ▲ +16.17% | ▲ +16.62% | $206.29 (+24.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access